Skip to content

Addiction: all studies

Page 800 of 855: studies 7,991 to 8,000 of 8,547, newest first. Back to the addiction overview

Research

Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine.

Brain Research February 28, 1997 Stanley D Glick, Isabelle M Maisonneuve, S M Pearl 38 citations

Ibogaine, a putatively anti-addictive alkaloid, binds to kappa-opioid and NMDA receptors. In the present study we investigated the roles of kappa-opioid and NMDA actions in mediating ibogaine's (40 mg/kg, i.p.) behavioral and neurochemical effects in rats. A combination of a kappa-opioid antagonist (norbinaltorphimine, 10 mg/kg, s.c.) and a NMDA agonist (NMDA, 20 mg/kg, i.p.) partially...

MDMA("Ecstasy")-Konsum - ein Überblick zu psychiatrischen und medizinischen Folgen

Fortschritte der Neurologie · Psychiatrie February 1, 1997 Rainer Thomasius, Margit Schmolke, Dana Kraus

Epidemiological research and Substance Abuse Warning Systems point to a sharp increase in the use of "Ecstasy" (MDMA), as well as to structural changes in the drug scene in and outside Europe. For some consumers, "Ecstasy" opens the door to the abuse of other illegal substances. Since the mid-eighties psychiatric complications and consequences of the abuse of MDMA have been reported in at least...

The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells

The FASEB Journal February 1, 1997 Rabi Simantov, M Tauber 89 citations

The widely abused amphetamine analog 3,4‐methylenecdioxymethamphetamine (MDMA, also called “ecstasy”) induces hallucination and psychostimulation, as well as long‐term neuropsychiatric behaviors such as panic and psychosis. In rodents and monkeys, MDMA is cytotoxic to serotonergic neurons, but this is less clear with humans. Herein, MDMA was cytotoxic to human serotonergic JAR cells; it altered...

Ibogaine and the dopaminergic response to nicotine.

Psychopharmacology February 1, 1997 Isabelle M Maisonneuve, G L Mann, C R Deibel et al. 38 citations

There is increasing evidence that the rewarding effect of nicotine is mediated by the mesolimbic dopamine system. The first objective of this study was to examine the dopamine response to repeated i.v. infusions of nicotine. Using in vivo microdialysis in awake and freely moving male Sprague-Dawley rats, we demonstrated that i.v. nicotine infusions (0.16 mg/kg or 0.32 mg/kg per infusion)...

Comments on "The ketamine model of the near-death experience: A central role for the N-methyl-D-aspartate receptor".

Journal of Near-Death Studies 1997 Antonio Bianchi 1 citation

Although ketamine can induce a state similar to a near-death experience (NDE), there is a striking difference between experiences induced by ketamine used in a recreational context and in an operating room. Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate receptor, as is ibogaine, the main alkaloid of a shrub used in Central Africa to induce NDEs in a religious context....

Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors.

Brain Research Bulletin 1997 Henry Sershen, Audrey Hashim, Ábel Lajtha 32 citations

Ibogaine is an indole alkaloid that has been of interest in recent years due to its putative efficacy in the treatment of drug dependence. For the most part, animal data have shown attenuation of some of the effects of stimulant drugs, for example, motor stimulation and self-administration. The mechanism of this inhibition of drug-induced behavior seems to suggest the action of the dopamine,...

Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors.

Molecular Pharmacology 1997 B Badio, W L Padgett, J W Daly 52 citations

Ibogaine noncompetitively blocked (IC50 approximately 20 nM) 22NaCl influx through ganglionic-type nicotinic receptor channels of rat pheochromocytoma PC12 cells. The major metabolite O-des-methylibogaine was 75-fold less active, and O-t-butyl-O-des-methylibogaine was 20-fold less active. Ibogaine was relatively weak as a blocker (IC50 approximately 2000 nM) of the neuromuscular-type nicotinic...

The effects of noribogaine and harmaline in rats trained with ibogaine as a discriminative stimulus.

Life Sciences 1997 Scott Helsley, R A Rabin, Jerrold C Winter 13 citations

In the present investigation, Fischer-344 rats were trained to discriminate 10.0 mg/kg of ibogaine from water using a pretreatment time of 60 minutes. Analysis of dose response data generated an ED50 of 4.6 mg/kg. The time course of the ibogaine (10.0 mg/kg) cue was also determined. The stimulus reached a maximum level of 94% ibogaine-appropriate responding at the 60-min pretreatment time. This...

Ibogaine and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic transmission in the rat parabrachial nucleus in vitro.

Brain Research Bulletin 1997 S B Kombian, T M Saleh, N I Fiagbe et al. 14 citations

Ibogaine is a natural alkaloid of Voacanga africana that is effective in the treatment of withdrawal symptoms and craving in drug addicts. As the synaptic and cellular basis of ibogaine's actions are not well understood, this study tested the hypothesis that ibogaine and Voacanga africana extract modulate neuronal excitability and synaptic transmission in the parabrachial nucleus using the...

Suppressive effect of mitragynine on the 5-methoxy-N,N-dimethyltryptamine-induced head-twitch response in mice.

Pharmacology, Biochemistry, and Behavior 1997 Kinzo Matsumoto, Maho Mizowaki, Hiromitsu Takayama et al. 60 citations

We investigated the effects of mitragynine, a major alkaloid isolated from the leaves of Mitragyna speciosa Korth (Rubiaceae), on the 5-HT2A receptor-mediated head-twitch response in mice. Intraperitoneal injection of mitragynine (5-30 mg/kg), as well as intraperitoneal injection of 5-HT2A receptor antagonist ritanserin, inhibited the 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT: 16 mg/kg,...